LGND
Ligand Pharmaceuticals Incorporated
Stock
$302.96+0.22 (+0.07%)Close Oct 2, 2026
Cash flow statement
| Line | Last 12 months | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $132M | $49M | $97M | $50M | $138M | $79M | $55M | −$29M | $194M | $89M | $61M | $42M | $21M | $21M | $161K | −$1.2M | −$27M | −$34M |
| Capital expenditures | $278K | $452K | $1.8M | $3.5M | $18M | $8.8M | $4.5M | $2.6M | $887K | $2.2M | $1.9M | $93K | $6K | $377K | $595K | $78K | $70K | $522K |
| Free cash flow | $131M | $49M | $95M | $46M | $120M | $70M | $50M | −$32M | $193M | $86M | $59M | $42M | $21M | $20M | −$434K | −$1.3M | −$27M | −$34M |
| Stock-based compensation | $53M | $47M | $41M | $26M | $60M | $39M | $31M | $25M | $21M | $25M | $19M | $12M | $11M | $5.7M | $4.1M | $3.4M | $2.3M | $3.4M |
| Buybacks | — | $15M | $0 | $0 | $0 | $0 | $78M | $453M | $123M | $2.0M | $3.9M | $489K | $68M | $0 | $0 | $55K | $91K | — |
| Free cash flow margin | 45.2% | 18.2% | 57.0% | 35.1% | 61.1% | 29.0% | 30.6% | −26.5% | 76.8% | 61.2% | 54.0% | 57.9% | 31.9% | 41.5% | −1.4% | −4.2% | −115.3% | −88.1% |